脾多肽联合补中益气丸对慢性阻塞性肺疾病急性加重期的控制效果研究

Control Effect of Spleen Polypeptide Combined with Buzhong Yiqi Pill on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的:分析脾多肽联合补中益气丸对慢性阻塞性肺疾病(慢阻肺)急性加重期的控制效果。方法:研究选取医院确诊慢阻肺急性加重期患者125例进行研究。观察组和对照组均在常规治疗的基础上进行干预研究;其中观察组患者接受脾多肽联合补中益气丸口服进行干预,对照组接受基础性沙美特罗替卡松粉吸入剂的常规干预。随访1年对比两组患者疗效情况。研究观察患者治疗后1周的疗效情况,比较两组患者的第1秒用力呼气容积FEV1、用力肺活量FCV水平以及FEV1/FCV水平等,同时比较患者的住院次数与发作次数等情况。结果:研究治疗前两组患者的肺功能水平差别未见统计学意义,而且在不同病情程度以及不同病程分层后的患者中差别也均未见统计学意义(P>0.05)。治疗后对比发现,两组患者肺功能水平均比治疗前有所改进,差别有统计学意义(P<0.05);不同病情程度和病程分层患者中也见到相似的趋势(均P<0.05);与对照组比较则提示,观察组患者肺功能改善情况均优于对照组(P<0.05)。两组患者治疗后的急性发作次数以及再次住院次数统计和比较也发现观察组患者急性发作次数与再次住院次数均低于对照组(P<0.05);对病情水平与病程分层后仍可见类似趋势。观察组患者CD^+3、CD^+4以及CD^+4/CD^+8等免疫指标水平治疗后高于治疗前,且优于对照组,P<0.05;IL-2和IL-6水平也均表现出同样的趋势,改善情况在观察组优于对照组;研究结果还提示,hs-CRP水平则可见观察组治疗后水平显著减低(P<0.05)。结论:脾多肽联合补中益气丸治疗阻肺急性加重期具有较高优势,能够显著提高患者肺功能,且治疗后的复发次数较少。

Objective:To analyze the effect of spleen peptide combined with Buzhong Yiqi Pill on the acute exacerbation of chronic obstructive pulmonary disease.Methods:A total of 125 patients with acute exacerbation of chronic obstructive pulmonary disease were enrolled in the study.Both the observation group and the control group were intervened on the basis of conventional treatment.Among them,the observation group received the spleen peptide combined with Buzhong Yiqi Pill for oral intervention,and the control group received the routine intervention of the basic salmeterol ticatica powder inhaler.The efficacy of the two groups was compared after 1 year follow-up.The patients were observed for 1 week after treatment.The first-second forced expiratory volume FEV1,forced vital capacity FCV level and FEV1/FCV level were compared between the two groups.The number of hospitalizations and the number of seizures were compared.Results:There was no statistically significant difference in lung function between the two groups before treatment,and there was no statistically significant difference in the degree of disease or stratification of different disease stages(P>0.05).After treatment,the lung function levels of the two groups were improved compared with those before treatment,and the difference was statistically significant(P<0.05).Similar trends were observed in patients with different disease severity and disease stratification(all P<0.05).Compared with the control group,the improvement of lung function in the observation group was better than that in the control group(P<0.05).The number of acute attacks and the number of re-hospitalizations in the two groups were also found in the observation group.The number of hospitalizations was lower than that of the control group(P<0.05).Similar trends were observed after the disease level and disease course were stratified.In the observation group,the levels of CD^+3,CD^+4 and CD^+4/CD^+8 were higher than those before treatment,and better than those of the control group(P<0.05).IL-2 and IL-6 levels also showed the same trend.The observation group was superior to the control group and the results also suggested that the hs-CRP level was significantly lower in the observation group after treatment(P<0.05).Conclusion:The spleen polypeptide combined with Chinese medicine Fuzhong Yiqi Pill has a high advantage in the treatment of acute exacerbation of obstructive pulmonary disease,which can significantly improve the lung function of patients and has fewer recurrences after treatment.